Politics
Election results and biopharma, Madrigal, Ultragenyx: The Readout Ultragenyx announced that it's laying off about 20% of its staff as it ends development of two rare disease drugs.
Ultragenyx announced that it's laying off about 20% of its staff as it ends development of two rare disease drugs.
Dr. Kai NakamuraChief Science CorrespondentPublished Nov 4, 2026 at 9:49 PM EST · 1 min read
Election results and biopharma, Madrigal, Ultragenyx: The Readout Ultragenyx announced that it's laying off about 20% of its staff as it ends development of two rare disease drugs. Ultragenyx announced that it's laying off about 20% of its staff as it ends development of two rare disease drugs.
Continue reading
Latest →Corrections, sourcing and article labels are part of the publication record. See our editorial standards.